AR045886A1 - Derivados de imidazol para el tratamiento de trastornos alergicos e hiperproliferativos - Google Patents

Derivados de imidazol para el tratamiento de trastornos alergicos e hiperproliferativos

Info

Publication number
AR045886A1
AR045886A1 ARP040101207A ARP040101207A AR045886A1 AR 045886 A1 AR045886 A1 AR 045886A1 AR P040101207 A ARP040101207 A AR P040101207A AR P040101207 A ARP040101207 A AR P040101207A AR 045886 A1 AR045886 A1 AR 045886A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
group
heterocycle
cycloalkyl
Prior art date
Application number
ARP040101207A
Other languages
English (en)
Inventor
Jagadish Sircar
Richard Thomas
Mark Richards
Haripada Khatuya
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of AR045886A1 publication Critical patent/AR045886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las realizaciones preferidas son pequenas moléculas inhibidoras de la respuesta de la IgE a alérgenos, que son útiles en el tratamiento de las alergias y/o el asma o cualquier enfermedad donde la IgE sea patogénica. Las realizaciones preferidas también se relacionan con moléculas de imidazol que son inhibidores de la proliferación celular y por lo tanto son útiles como agentes anticancerígeno. Las realizaciones preferidas además se relacionan con pequenas moléculas las cuales suprimen las citoquinas y los leucocitos. Reivindicación 1: Una composición farmacéutica para tratar o prevenir una reacción alérgica asociada con niveles incrementados de IgE o para inhibir la proliferación celular en un mamífero que comprende uno o más de cualquiera del resto de grupo de fórmulas (1), donde R se selecciona entre el grupo que consiste en H, alquilo C1-5, bencilo, p-fluorobencilo, y dialquilaminoalquilo, donde dicho alquilo C1-5 se selecciona entre el grupo que consiste en un alquilo de cadena lineal, ramificada o cíclica; donde R3, X y Y se seleccionan en forma independiente entre el grupo que consiste en H, halógeno, alcoxi, alcoxi, sustituido, alquilo, alquilo sustituido, dialquilaminoalquilo, hidroxialquilo, OH, OCH3, COOH, CN, CF3, OCF3, NO2, COOR'', CHO, y COR''; donde R1 y R2 se seleccionan en forma independiente entre el grupo que consiste en H, alquilo, alquilo sustituido, cicloalquilo C3-9, cicloalquilo C3-9 sustituido, grupos alifáticos policíclicos, fenilo, fenilo sustituido, naftilo, naftilo sustituido, heterociclo, y heterociclo sustituido, donde dicho heterociclo y dicho heterociclo sustituido contienen 1-3 heteroátomos, donde dicho heteroátomo se selecciona en forma independiente entre el grupo que consiste en nitrógeno, oxígeno y azufre; donde dichos sustituyentes se seleccionan entre el grupo que consisten en H, halógeno, alcoxi, alcoxi sustituido, alquilo, alquilo sustituido, dialquilaminoalquilo, hidroxialquilo, OH, OCH3, COOH, COOR', COR', CN, CF3, OCF3, NO2, NR'R', NHCOR' y CONR'R'; donde R' se selecciona entre el grupo que consiste en H, alquilo, alquilo sustituido, cicloalquilo C3-9, cicloalquilo C3-9 sustituido, grupos alifáticos policíclicos, fenilo, fenilo sustituido, naftilo, naftilo sustituido, heteroarilo, y heteroarilo sustituido, donde dicho heteroarilo y dicho heteroarilo sustituido contienen 1-3 heteroátomos, donde dicho heteroátomo se selecciona en forma independiente entre el grupo que consiste en nitrógeno, oxígeno y azufre; y donde R'' se selecciona entre el grupo que consiste en alquilo C1-9, donde dicho alquilo C1-9 se selecciona entre el grupo que consiste en alquilo de cadena lineal, alquilo ramificado, y alquilo cíclico. Reivindicación 2: El compuesto de la reivindicación 1, en el cual dicho grupo alifático policíclico se selecciona entre el grupo que consiste en adamantilo, bicicloheptilo, camforilo, biciclo[2,2,2]octanilo, y norbonilo. Reivindicación 3: El compuesto de la reivindicación 1, en el cual dicho heterociclo y dicho heterociclo sustituido se selecciona entre el grupo que consiste en piridinas, tiazoles, isotiazoles, oxazoles, pirimidinas, pirazinas, furanos, tiofenos, isoxazoles, pirroles, piridazinas, 1,2,3-triazinas, 1,2,4-triazinas, 1,3,5-triazinas, pirazoles, imidazoles, indoles, quinolinas, iso-quinolinas, benzotiofinas, benzofuranos, paratiazinas, piranos, cromenos, pirrolidinas, pirazolidinas, imidazolidinas, morfolinas, tiomorfolinos, y los heterociclos saturados correspondientes.
ARP040101207A 2003-04-10 2004-04-12 Derivados de imidazol para el tratamiento de trastornos alergicos e hiperproliferativos AR045886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46209003P 2003-04-10 2003-04-10

Publications (1)

Publication Number Publication Date
AR045886A1 true AR045886A1 (es) 2005-11-16

Family

ID=33299906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101207A AR045886A1 (es) 2003-04-10 2004-04-12 Derivados de imidazol para el tratamiento de trastornos alergicos e hiperproliferativos

Country Status (15)

Country Link
US (1) US20040229927A1 (es)
EP (1) EP1613310A1 (es)
JP (1) JP2006522820A (es)
KR (1) KR20050120711A (es)
CN (1) CN1826111A (es)
AR (1) AR045886A1 (es)
AU (1) AU2004229466A1 (es)
BR (1) BRPI0409097A (es)
CA (1) CA2521841A1 (es)
MX (1) MXJL05000041A (es)
PL (1) PL378919A1 (es)
RU (1) RU2005134670A (es)
TW (1) TW200503695A (es)
WO (1) WO2004091610A1 (es)
ZA (1) ZA200508108B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CN101022728B (zh) * 2004-03-25 2012-08-08 詹森药业有限公司 咪唑化合物
CN101490046A (zh) 2006-05-09 2009-07-22 辉瑞产品公司 环烷基氨基酸衍生物及其药物组合物
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
RU2514427C2 (ru) 2008-06-16 2014-04-27 Юниверсити Оф Теннесси Рисёч Фаундейшн Соединения для лечения рака
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP3066079B1 (de) 2013-11-05 2018-05-09 Bayer CropScience Aktiengesellschaft Substituierte benzamide zur behandlung von arthropoden
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
WO2017190086A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CA3036195A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2018140504A1 (en) * 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
CN108191667B (zh) * 2018-01-04 2021-03-26 利尔化学股份有限公司 2-硝基-4-三氟甲基苯甲酸甲酯的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206257A (en) * 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) * 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
JPH01224759A (ja) * 1988-03-03 1989-09-07 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
JPH01225949A (ja) * 1988-03-04 1989-09-08 Konica Corp ハロゲン化銀写真感光材料
JPH01262546A (ja) * 1988-04-13 1989-10-19 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
JPH0361946A (ja) * 1989-07-29 1991-03-18 Konica Corp ハロゲン化銀カラー写真感光材料
JPH03245140A (ja) * 1990-02-23 1991-10-31 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
US5646281A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
JPH09304897A (ja) * 1996-05-10 1997-11-28 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
CA2232467A1 (en) * 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
CN1826111A (zh) 2006-08-30
MXJL05000041A (es) 2005-12-22
RU2005134670A (ru) 2006-06-10
CA2521841A1 (en) 2004-10-28
TW200503695A (en) 2005-02-01
AU2004229466A1 (en) 2004-10-28
ZA200508108B (en) 2007-03-28
BRPI0409097A (pt) 2006-04-11
EP1613310A1 (en) 2006-01-11
US20040229927A1 (en) 2004-11-18
JP2006522820A (ja) 2006-10-05
KR20050120711A (ko) 2005-12-22
WO2004091610A1 (en) 2004-10-28
PL378919A1 (pl) 2006-06-12

Similar Documents

Publication Publication Date Title
AR045886A1 (es) Derivados de imidazol para el tratamiento de trastornos alergicos e hiperproliferativos
PE20011334A1 (es) Compuestos y composiciones de indazol de formula (i)
AR124687A2 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
AR041251A1 (es) Compuestos de fenilindol para modular la ige e inhibir la proliferacion celular
RS20050201A (en) Heterocyclic compounds
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
HN2009001276A (es) Derivados de espirocromanona sustituida como inhibidores de acc
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
PE20151072A1 (es) Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20030200A1 (es) Bencimidazol como inhibidores de las map quinasas
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
UY30823A1 (es) Piperidinas sustituidas que contienen una fraccion de heteroarilamida o heteroarilfenilo
BRPI0413059A (pt) derivados de piridila e seu uso como agentes terapêuticos
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
ATE368657T1 (de) Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
NO20054598L (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20130650A1 (es) Derivados de tetrahidro-pirido-pirimidina
ECSP088598A (es) Derivados de piridazinona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal